Department of Pathology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; and.
Lymphoma and Myeloma Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Care and Research), Amsterdam, The Netherlands.
Blood. 2021 Apr 1;137(13):1713-1718. doi: 10.1182/blood.2020008188.
Plasma cells no longer express a B-cell antigen receptor and are hence deprived of signals crucial for survival throughout B-cell development. Instead, normal plasma cells, as well as their malignant myeloma counterparts, heavily rely on communication with the bone marrow (BM) microenvironment for survival. The plasma cell heparan sulfate proteoglycan (HSPG) syndecan-1 (CD138) and HSPGs in the BM microenvironment act as master regulators of this communication by co-opting specific growth and survival factors from the BM niche. This designates syndecan-1/HSPGs and their synthesis machinery as potential treatment targets in multiple myeloma.
浆细胞不再表达 B 细胞抗原受体，因此失去了 B 细胞发育过程中至关重要的生存信号。相反，正常浆细胞及其恶性骨髓瘤对应物严重依赖与骨髓 (BM) 微环境的交流来生存。浆细胞硫酸乙酰肝素蛋白聚糖 (HSPG) 连接蛋白-1 (CD138) 和 BM 微环境中的 HSPGs 充当这种交流的主调控因子，从 BM 龛位中招募特定的生长和存活因子。这将连接蛋白-1/HSPGs 及其合成机制指定为多发性骨髓瘤的潜在治疗靶点。
